Follicular Lymphoma

Follicular lymphoma is one of the most common kinds of non-Hodgkin lymphoma. Its progression rate varies widely, though it tends to spread slowly and has few symptoms. Patients with follicular lymphoma usually survive ten years or longer.
What is Follicular Lymphoma?

Follicular lymphoma is a cancer of the B-cells that accounts for around one third of all cases of lymphoma. The cancer is a form of non-Hodgkin lymphoma that usually affects adults, with an average age-at-diagnosis of 60. Follicular lymphoma is more common among women than among men.

Read More

Overview

Feature Articles

Latest Follicular Lymphoma News and Research

Study unlocks protein clues to aggressive lymphoma transformation

Study unlocks protein clues to aggressive lymphoma transformation

New antibody combination shows 'surprising' results in high-risk follicular lymphoma trial

New antibody combination shows 'surprising' results in high-risk follicular lymphoma trial

Gene splicing determines CD20 levels and response to monoclonal antibody therapy

Gene splicing determines CD20 levels and response to monoclonal antibody therapy

University of Vermont Cancer Center to offer a novel, highly effective form of cancer treatment

University of Vermont Cancer Center to offer a novel, highly effective form of cancer treatment

Evaluating a third SARS-CoV-2 mRNA vaccine in anti-CD20-treated patients

Evaluating a third SARS-CoV-2 mRNA vaccine in anti-CD20-treated patients

Study investigates recombinant SARS-CoV-2 variants in immunocompromised individuals

Study investigates recombinant SARS-CoV-2 variants in immunocompromised individuals

New grant program launches to advance therapeutic discovery for follicular lymphoma

New grant program launches to advance therapeutic discovery for follicular lymphoma

Clinical studies show enhanced responses for lymphoma patients treated with axi-cel CAR T cell therapy

Clinical studies show enhanced responses for lymphoma patients treated with axi-cel CAR T cell therapy

International collaboration secures €1M grant to investigate new treatment target for lymphoma

International collaboration secures €1M grant to investigate new treatment target for lymphoma

Implications of persistent SARS-CoV-2 infection in patients with lymphoid malignancies

Implications of persistent SARS-CoV-2 infection in patients with lymphoid malignancies

New integrative NGS panel for analysis of standard and novel biomarkers in lymphoid neoplasms

New integrative NGS panel for analysis of standard and novel biomarkers in lymphoid neoplasms

SwRI researchers part of two collaborative teams receive SAMF bioscience grants

SwRI researchers part of two collaborative teams receive SAMF bioscience grants

Clinical trial shows five-year outcomes of CAR T-cell therapy for non-Hodgkin lymphomas

Clinical trial shows five-year outcomes of CAR T-cell therapy for non-Hodgkin lymphomas

Prolonged shedding and multiple mutations 154 days after initial SARS-CoV-2 diagnosis reported

Prolonged shedding and multiple mutations 154 days after initial SARS-CoV-2 diagnosis reported

MDC researchers develop a potent weapon against lymphomas

MDC researchers develop a potent weapon against lymphomas

Researchers evaluate safety of novel therapy for patients with non-Hodgkin lymphoma

Researchers evaluate safety of novel therapy for patients with non-Hodgkin lymphoma

Study: CAR T-cell therapy reduced cancer cells in patients with advanced non-Hodgkin lymphoma

Study: CAR T-cell therapy reduced cancer cells in patients with advanced non-Hodgkin lymphoma

More than 40 Dana-Farber studies to be presented at the virtual 62nd ASH Annual Meeting

More than 40 Dana-Farber studies to be presented at the virtual 62nd ASH Annual Meeting

Yale and AI Therapeutics launch clinical trial of potential COVID-19 drug

Yale and AI Therapeutics launch clinical trial of potential COVID-19 drug

Combining two immunotherapies into a single treatment found to be more effective

Combining two immunotherapies into a single treatment found to be more effective